Key result
Touch screen depression screening using the PHQ-9 in cancer patients was highly feasible, with ≥97% completing the PHQ-2 and ≥96% completing the PHQ-9 when triggered.
Why the study?
Is depression screening using the PHQ-9 administered on a touch screen computer feasible and valid in cancer patients?
Population
342 cancer patients in medical oncology, radiation oncology, and hematopoietic stem cell transplantation…
Design
Cohort
Follow-up
Prior to therapy (T1) and during therapy (T2)
Authors
Loading...
May support routine PHQ-9 screening in oncology clinics; leaves open prospective validation of clinical utility.
Observational (n=342)
Is depression screening using the PHQ-9 administered on a touch screen computer feasible and valid in cancer patients?
The PHQ-9 administered on a touch screen computer is a feasible and valid method for depression screening in diverse cancer populations.
Fann et al. (2008) conducted an observational in Cancer (n=342). Touch screen depression screening using the Patient Health Questionnaire-9 (PHQ-9) was evaluated on Feasibility (completion rate of PHQ-2). Touch screen depression screening using the PHQ-9 in cancer patients was highly feasible, with ≥97% completing the PHQ-2 and ≥96% completing the PHQ-9 when triggered.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: